8 completed, 3 unknown, 1 recruiting, 1 terminated. 13 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 8, Unknown 3, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow COVID-19 Vaccine: new trials by email Literature Review of COVID-19 Vaccine trials Research Report on COVID-19 Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pancoronavirus Vaccine Study in Healthy Adults CoV-RBD-scNP-001 and 3M-052-AF - COVID-19 Respiratory Infection, SARS CoV 2 Infection | Phase 1 | Terminated | Duke University | 4 | 2025-08-01 | 2026-10-19 |
| Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine Thymalfasin (Thymosin alpha 1, Ta1) - Vaccine Response, COVID-19 Vaccine | Phase 1 | Recruiting | The Methodist Hospital Research Institute | 75 | 2024-12-02 | 2026-07-16 |
| Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination 30μg dose of LYB002V14, 60μg dose of LYB002V14, placebo - SARS-CoV-2, COVID-19 Vaccine | Phase 1 | Unknown | Guangzhou Patronus Biotech Co., Ltd. | 120 | 2023-12-26 | 2023-12-26 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 MVC-COV1901, MVC-COV1901(Beta)-15, MVC-COV1901(Beta)-25 - COVID-19 Vaccine | Phase 1 | Completed | Medigen Vaccine Biologics Corp. | 107 | 2022-05-06 | 2023-03-15 |
| ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2) - COVID-19 Vaccine | Phase 1 | Completed | Laboratorio Pablo Cassara S.R.L. | 80 | 2022-04-20 | 2023-12-22 |
| Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease 25 Baiya SARS-CoV-2 Vax 2, 50 Baiya SARS-CoV-2 Vax 2 - COVID-19 Vaccine | Phase 1 | Unknown | Baiya Phytopharm Co., Ltd. | 24 | 2022-03-28 | 2023-05-24 |
| Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers EG-COVID-003, EG-COVID-001, A: EG-COVID - COVID-19 Vaccine | Phase 1 / Phase 2 | Completed | EyeGene Inc. | 67 | 2022-03-22 | 2025-03-07 |
| ChulaCov19 Vaccine in Healthy Adults ChulaCov19 vaccine, Placebo - COVID-19 Vaccine, Safety Issues | Phase 1 / Phase 2 | Completed | Chulalongkorn University | 192 | 2021-05-03 | 2023-02-09 |
| Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Normal Saline, NDV-HXP-S vaccine - Covid-19, SARS Pneumonia | Phase 1 / Phase 2 | Completed | Mahidol University | 455 | 2021-03-20 | 2022-11-15 |
| Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine, Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine, Placebo - COVID-19 Vaccine | Phase 1 | Unknown | Kocak Farma | 38 | 2021-03-19 | 2021-04-13 |
| A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1) COVIVAC, Phosphate-buffered saline - COVID-19 Disease, SARS Pneumonia | Phase 1 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 120 | 2021-03-10 | 2025-02-13 |
| Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults multipeptide cocktail - COVID-19 Vaccine | Phase 1 | Completed | University Hospital Tuebingen | 36 | 2020-11-27 | 2022-03-02 |
| Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC ERUCOV-VAC, Placebo Vaccine - COVID-19 Vaccine | Phase 1 | Completed | Health Institutes of Turkey | 44 | 2020-11-05 | 2023-02-14 |
COVID-19 (8) · Pneumonia, Viral (2) · Sedentary Behavior (1)
Coronaviridae Infections (8) · Coronavirus Infections (8) · Infections (8) · Lung Diseases (8) · Nidovirales Infections (8) · Pneumonia (8) · RNA Virus Infections (8) · Respiratory Tract Diseases (8) · Respiratory Tract Infections (8) · Virus Diseases (8) · Pneumonia, Viral (6) · Behavior (1)
COVAC-1 COVID-19 vaccine (1) · COVI-VAC (1) · ChulaCov19 vaccine (1) · MVC-COV1901 vaccine (1) · NDV-HXP-S COVID-19 vaccine (1) · Saline Solution (1) · TURKOVAC (1) · Thymalfasin (1) · Trace amine-associated receptor 1 (1) · Vaccination (1) · Vaccines (1)
Baiya Phytopharm Co., Ltd. (1) · Chulalongkorn University (1) · Duke University (1) · EyeGene Inc. (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Health Institutes of Turkey (1) · Institute of Vaccines and Medical Biologicals, Vietnam (1) · Kocak Farma (1) · Laboratorio Pablo Cassara S.R.L. (1) · Mahidol University (1) · Medigen Vaccine Biologics Corp. (1) · The Methodist Hospital Research Institute (1) · University Hospital Tuebingen (1)
Thailand (3) · Turkey (Türkiye) (2) · United States (2) · Argentina (1) · Australia (1) · China (1) · Germany (1) · Taiwan (1) · Vietnam (1)
Allen Lien, MD Dr.Ph (1) · Aydin Erenmemisoglu, Prof. (1) · Kiat Ruxrungtham, MD (1) · Mark Bloch, A/Prof (1) · Punnee Pitisutthithum (1) · Qin Yu, Master (1) · Turgay Celik, Prof. (1) · Zafer Sezer (1)
PMID 34580673, PMID 35284808, PMID 35577631, PMID 36460536, PMID 37507392, PMID 38287068